Sterkem Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 17-12-2024
- Paid Up Capital ₹ 0.20 M
as on 17-12-2024
- Company Age 22 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.10 M
as on 17-12-2024
- Revenue 23.48%
(FY 2022)
- Profit -24.85%
(FY 2022)
- Ebitda 5.60%
(FY 2022)
- Net Worth 51.29%
(FY 2022)
- Total Assets 6.93%
(FY 2022)
About Sterkem Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹1.10 M.
Heena Patel and Ajit Desai serve as directors at the Company.
- CIN/LLPIN
U51909MH2002PTC135324
- Company No.
135324
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 2002
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sterkem Pharma Private Limited offer?
Sterkem Pharma Private Limited offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs.
Who are the key members and board of directors at Sterkem Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Heena Patel  | Director | 01-Apr-2015 | Current |
| Ajit Desai | Director | 28-Mar-2002 | Current |
Financial Performance of Sterkem Pharma.
Sterkem Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 23.48% increase. The company also saw a substantial fall in profitability, with a 24.85% decrease in profit. The company's net worth Soared by an impressive increase of 51.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sterkem Pharma?
Unlock access to Sterkem Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
E M Pharmaceuticals Private LimitedActive 32 years 8 monthsHeena Patel and Ajit Desai are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 13 Nov 2023 | ₹1.10 M | Open |
How Many Employees Work at Sterkem Pharma?
Sterkem Pharma has a workforce of 119 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sterkem Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sterkem Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
